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treatment time and simple radioprotection measures should position 
this new medical device as an interesting alternative for breast IORT.  
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Purpose/Objective: To analyze prognostic factors associated with 
survival in patients after intensified radio-surgical rescue of 
oligorecurrent pelvic cancer, particularly the influence of external 
beam radiation therapy (EBRT).  
Materials and Methods: From January 1995 to december 2011, 81 
patients [colorectal (46%); gynecologic (26%); retroperitoneal sarcoma 
(18%)] underwent extended surgery [multiorgan (58%), bone (23%), 
vascular (9%), soft tissue (43%)] and intraoperative electron-beam 
radiation therapy [IOERT (10-15 Gy)] to the pelvic recurrence tumor 
bed. 35 (43%) of these patients also received EBRT (30.6-50.4 Gy). 
Survival outcomes were estimated using the Kaplan-Meier method, 
and risk factors were identified by univariate and multivariate 
analyses.  
Results: Median follow-up was 34 months (3-189 months), and the 1- 
3-, and 5-year rates of locoregional control (LRC) were 83%, 53%, and 
41%, respectively. Univariate Cox proportional hazard analysis 
revealed worse LRC for those patients who did not received integrated 
EBRT treatment for the pelvic recurrence rescue (p=0.003), and had 
non-radical resection (p=0.01). On multivariate analysis, integrated 
EBRT treatment, non-radical resection, and tumor fragmentation 
retained significance (p=0.002,p=0.004, and p=0.05, respectively).  
Conclusions: EBRT treatment integrated for rescue, radical resection, 
and abscence of tumor fragmentation are associated with improved 
LRC in patients with oligorecurrent pelvic cancer. Present results 
suggest that patients with oligorecurrent pelvic disease ma ybenefit 
from EBRT treatment integrated with extended surgery and IOERT. 
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Purpose/Objective: To analyze prognostic factors associated with 
survival in patients after intraoperative electrons containing resective 
surgical rescue of locally recurrent rectal cancer (LRRC), particularly 
the influence of an integrated component of external beam radiation 
therapy (EBRT).  
Materials and Methods: From January 1995 to december 2011, 60 
patients with pelvic recurrence from rectal inicial cancer primaries 
underwent extended surgery [n=38; multiorgan(43%), bone (28%), soft 
tissue (38%)] or non-extended (n=22) surgical resection, including a 
component of intraoperative electron-beam radiation therapy (IOERT) 
to the pelvic recurrence tumor bed. Twenty-eight (47%) of these 
patients were amenable and also received EBRT (range, 30.6-50.4 Gy). 
Survival outcomes were estimated using the Kaplan-Meier method, 
and risk factors were identified by univariate and multivariate 
analyses.  
Results: Median follow-up was 36 months (range, 2-189), the 1- 3-, 
and 5-year rates of LRC were 86%, 52%, and 44%, respectively. On 
univariate analysis, patients with R1 resection (5-year LRC=55.7% vs. 
19.0%, p=0.02) and not receiving EBRT (5-year LRC= 56.2% vs. 32.0%, 
p=0.02) were at a significantly higher risk of LR recurrence. Patients 
without tumor fragmentation, non-metastasic lymph nodes, abscence 
of perineural invasion and age > 55 had a lower risk of LRrelapse. We 
observed on multivariate analysis that margin status (R1resection), 
EBRT at the time of pelvic recurrence, no tumor fragmentation and 
non-lymph node metastasis retained significance with regard to LR 
relapse.  
Conclusions: EBRT treatment integrated for rescue, resection 
radicality, and not involved fragmented resection specimens are 
associated with improved LRC in patients with locally recurrent rectal 
cancer. Additionaly tumor fragmentation could be compensated by 
EBRT. Present results suggest that a significant group of patients with 
oligorecurrent pelvic disease may benefit from EBRT treatment 
integrated with extended surgery and IOERT. 
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Purpose/Objective: Patients with locally advanced rectal cancer are 
reported to have a dismal prognosis, challenging expert 
interdisciplinary manaegment. The purpose of this study is to analyze 
the 15-years results of neoadjuvant-based multimodality treatment 
for locally advanced rectal cancer (LARC) with particular emphasis on 
intraoperative electron-beam radiotherapy (IEORT). 
Materials and Methods: A total of 335 patients with LARC [≥cT3 93% 
and/or cN+ 69%) who underwent multimodality treatment between 
1995 and 2011 were studied. The basic treatment principle was 
preoperative(chemo)radiotherapy, intended radical surgery, IOERT 
and elective adjuvant chemotherapy (aCT). In uni- and multivariate 
analyses, risk factors for all loco-regional recurrence (LR), IOERT in-
field recurrence (IFR) and IOERT out-field recurrence (OFR) were 
studied. 
Results: Median follow-up for all patients was 52. 2 months (range, 1-
184), the 5 year overall survival, disease-free survival, local control, 
in-field and out-field control rates were 73.6%, 69.4%, 94.4%, 97.0% 
and 93.4%, respectively. Synchronic local and distant metastasic 
disease was present in 16% of the patients that recurred. In 
multivariate analysis distal margin distance < 20 mm [HR 3.74 (1.79-
7.82),p < 0.001], ypN+ [HR 2.53 (1.16-5.54), p = 0.02] and tumor 
histology grade 3[HR 7.0 (2.8-17.56), p < 0.001]; Non-sphincter 
preserving surgery [HR 6.49(1.58-26.32), p=0.009], cT4 [HR 6.24 (1.34-
29.1)], ypN+ [HR 7.41 (1.96-28.0)] and tumor histology grade 3 [HR 8.5 
(2.8.-27.44), p < 0.001]; gender [HR 2.87 (1.10-7.46), p = 0.03], distal 
margin distance < 20 mm [HR 4.37 (1.68-11.34), p = 0.002] and no aCT 
[HR 2.62(1-03-1.68), p = 0.04] were associated with increased risk of 
LR, IFR and OFR, respectively.  
Conclusions: Overall oncological results after multimodality 
treatment of LARC are promising. The positive impact of 
intraoperative radiotherapy on pelvic control does justify the inclusion 
of this therapeutic modality in prospective multi-institutional trials. 
Cancer death with uncontrolled pelvic progression was 28%. Adding 
aCT to the treatment may contribute to improve LR rates.  
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